



BLA 761420/S-001

## SUPPLEMENT APPROVAL

CELLTRION, Inc.  
c/o Parexel International  
Attention: Ally Danta  
Regulatory Affairs Consultant  
2520 Meridian Parkway  
Suite 100  
Durham, NC 27713

Dear Ally Danta:

Please refer to your supplemental biologics license application (sBLA) received April 30, 2025, and your amendments, submitted under section 351(k) of the Public Health Service Act for Avtozma (tocilizumab-anoh) injection.

This Category B Prior Approval supplemental biologics license application provides for addition of Cytokine Release Syndrome (CRS) indication to USPI.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,<sup>1</sup> that is identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

- Cytokine Release Syndrome (CRS)  
At this time, we have determined that, with respect to this indication in pediatric patients 0 to <2 years of age, no pediatric studies will be required under PREA for your sBLA. You have provided a pediatric assessment for CRS in pediatric patients 2 years of age and older, and nothing is further required for this indication.

We remind you that there is a postmarketing requirement listed in the January 24, 2025, approval letter that is still open.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 601.12(f)(4)]. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.

If you have questions, contact Anh-Thy Ly, Project Manager, at 240-402-1001 or [Anh-Thy.Ly@fda.hhs.gov](mailto:Anh-Thy.Ly@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Raj Nair, MD  
Division Director  
Division of Rheumatology and Transplant  
Office of New Drug  
Center for Drug Evaluation and Research

### ENCLOSURES:

#### Branded Product Labeling

- Content of Labeling
  - Prescribing Information
  - Medication Guide

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

○ Instructions for Use  
Unbranded Biological Product Labeling

- Content of Labeling
  - Prescribing Information
  - Medication Guide
  - Instructions for Use

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

RAJ NAIR  
07/29/2025 02:26:29 PM